View More Recent Stories

Sep 27, 2022 08:11AM Twitter, JetBlue, Lucid Group Rise Premarket; Avidity, Ferguson Fall
Sep 27, 2022 07:03AM UPDATE: Avidity Biosciences Inc. (RNA) Announces FDA Partial Clinical Hold on New Participant Enrollment in Phase 1/2 Trial
Sep 27, 2022 07:00AM Avidity Biosciences Announces FDA Partial Clinical Hold on New Participant Enrollment in Phase 1/2 MARINA™ Trial
Sep 7, 2022 06:00AM Avidity Biosciences Engages with Patient Communities During National Muscular Dystrophy Awareness Month as part of Commitment to Developing Muscular Dystrophy Programs
Sep 1, 2022 09:05AM Avidity Biosciences to Participate in Upcoming Investor Conferences
Aug 9, 2022 04:05PM Avidity Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights
Aug 2, 2022 08:00AM Avidity Biosciences Enrolls Patients in the MARINA™ Open-Label Extension Study
Jun 17, 2022 08:00AM Avidity Biosciences Supports World Facioscapulohumeral Muscular Dystrophy (FSHD) Day and Presents Preclinical Data from FSHD Program
Jun 9, 2022 09:00AM Avidity Biosciences Announces Upcoming Presentations at the 29th Annual FSHD Society International Research Congress
May 10, 2022 04:05PM Avidity Biosciences Reports First Quarter 2022 Financial Results and Recent Highlights
Apr 5, 2022 09:00AM Avidity Biosciences Expands Role of Michael MacLean to Chief Financial and Chief Business Officer
Mar 29, 2022 09:00AM Avidity Biosciences Announces Upcoming Presentations at the American Academy of Neurology 2022 Annual Meeting
Mar 7, 2022 09:00AM Avidity Biosciences Announces Upcoming Presentations at the 2022 MDA Clinical & Scientific Conference
Mar 1, 2022 04:05PM Avidity Biosciences Reports Fourth Quarter and Year-End 2021 Financial Results and Recent Highlights
Feb 28, 2022 09:00AM Avidity Biosciences Honors Rare Disease Day®
Feb 23, 2022 09:01AM Avidity Biosciences Inc. (RNA) Appoints Steve Hughes as Chief Medical Officer
Feb 23, 2022 09:00AM Avidity Biosciences Appoints Steve Hughes, M.D., as Chief Medical Officer
Feb 11, 2022 04:05PM Avidity Biosciences to Participate in Upcoming Investor Conferences
Dec 9, 2021 09:00AM Avidity Biosciences Highlights FSHD Program at Virtual Investor and Analyst Event
Nov 9, 2021 04:05PM Avidity Biosciences Reports Third Quarter 2021 Financial Results and Recent Highlights
Nov 4, 2021 09:00AM Avidity Announces First Person Dosed with an Antibody Oligonucleotide Conjugate (AOC™)
Nov 2, 2021 04:05PM Avidity Biosciences to Participate in Upcoming Investor Conferences
Oct 18, 2021 09:00AM FDA Grants Fast Track Designation to AOC 1001 for the Treatment of Myotonic Dystrophy Type 1
Aug 31, 2021 09:30AM Avidity Biosciences to Participate in Upcoming Investor Conferences
Aug 25, 2021 04:13PM Avidity Biosciences Inc. (RNA) Appoints Eric Mosbrooker to its Board; Announces Departure of Roderick Wong
Aug 25, 2021 04:05PM Avidity Biosciences Announces Changes to its Board of Directors
Aug 24, 2021 08:32AM Avidity Biosciences Inc. (RNA) Announces European Medicines Agency Grants Orphan Designation for AOC 1001
Aug 24, 2021 08:30AM European Medicines Agency (EMA) Grants Orphan Designation for AOC 1001
Aug 16, 2021 08:30AM Avidity Biosciences Enters Into Collaboration with FSHD Clinical Trial Network to Support Development of Biomarkers for Future Clinical Trial Use
Aug 9, 2021 04:05PM Avidity Biosciences Reports Second Quarter 2021 Financial Results and Recent Highlights
Aug 2, 2021 08:03AM Avidity Biosciences Inc. (RNA) Receives IND Clearance from FDA to Proceed with the Phase 1/2 MARINA™ Trial of AOC 1001 in Adults with Myotonic Dystrophy
Aug 2, 2021 08:00AM Avidity Biosciences Receives IND Clearance from FDA to Proceed with the Phase 1/2 MARINA™ Trial of AOC 1001 in Adults with Myotonic Dystrophy (DM1)
May 19, 2021 09:00AM Avidity Biosciences Announces Updates on the Pipeline and Platform at Virtual Investor and Analyst Event
Oct 27, 2014 01:55PM Prosensa Holding (RNA) CEO to Appear on CNBC's Fast Money
View More Recent Stories